Search Results
Your search for japan matches 645 pages
Showing 601 - 6452015 Oncology Meetings
OCTOBER Advances in Cancer ImmunotherapyTMOctober 2 • Nashville, Tennessee For more information: www.sitcancer.org/sitc-meetings/aci2015/tn Institute for Clinical Immuno-Oncology (ICLIO) 1st Annual National ConferenceOctober 2 • Philadelphia, Pennsylvania For more information:...
Measuring Global Health Issues, Seven Billion Times
BOOKMARK Title: Epic Measures: One Doctor. Seven Billion PatientsAuthor: Jeremy N. SmithPublisher: Harper WavePublication date: April 7, 2015Price: $26.99; hardcover, 352 pages Health measures are essential tools in assessing public health and safety. Collecting large amounts of data is a laborious ...
2015 Oncology Meetings
OCTOBER ASTRO’s 57th Annual MeetingOctober 18-21 • San Antonio, Texas For more information: www.astro.org/Meetings-and-Events/2015-Annual-Meeting/Index.aspx 2015 International Cancer Education ConferenceOctober 21-23 • Tucson, Arizona For more information: http://2015.attendicec.org ACCC 32nd...
AZD9291 Updates Encouraging for Treatment-Resistant NSCLC
At the 16th World Conference on Lung Cancer, several studies showed consistent activity with the investigational third-generation inhibitor AZD9291 in patients with advanced non–small cell lung cancer (NSCLC) that is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors....
2015 Oncology Meetings
OCTOBER Modern Management of Urologic Cancers: A Multidisciplinary Approach (Memorial Sloan Kettering) October 29-31 • New York, New York For more information: http://www.themerzgroup.com/mskcc/mskcc-urologic-conference/ Lynn Sage Breast Cancer SymposiumOctober 29-November 1 • Chicago, Illinois...
2015 Oncology Meetings
NOVEMBER Best of ASTRONovember 13-14 • San Diego, California For more information: www.astro.org/Meetings-and-Events/2015-Best-of-ASTRO/Index.aspx 2015 Oncologic Emergency Medicine Conference November 13-14 • Houston, Texas For more information:...
2015 Oncology Meetings
DECEMBER Markers in Cancer 2015December 1-2 • Brussels, Belgium For more information: http://markersincancer.org 9th European Colorectal Congress (ECC)December 1-4 • St.Gallen, Switzerland For more information: www.colorectalsurgery.eu Advances in Cancer ImmunotherapyTMDecember 4 • New Orleans,...
2015-2016 Oncology Meetings
DECEMBER American Society for Cell Biology Annual MeetingDecember 12-16 • San Diego, California For more information: http://ascb.org/2015meeting/ ESMO Asia 2015 CongressDecember 18-21 • Singapore For more information: www.esmo.org/Conferences/ESMO-Asia-2015-Congress JANUARY 2016 4th AACR-IASLC...
2016 Oncology Meetings
JANUARY 2016 4th AACR-IASLC International Joint Conference: Lung Cancer Translational ScienceJanuary 4-7 • San Diego, CaliforniaFor more information: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=74#.VbbijqTbJjo Genitourinary Cancers SymposiumJanuary 7-9 • San Francisco,...
ASCO Endorsement of ACCP Guideline on Treating SCLC: Moving Forward to Better Outcomes in Oncology
In the current climate of rising health-care costs, particularly in the field of oncology, clinical guidelines provide a crucial tool to guide practitioners in evidence-based care and to improve the quality and consistency of care.1 The ASCO review and endorsement of the American College of Chest...
Patients With Incomplete Response to Neoadjuvant Chemotherapy Benefit From Capecitabine
Treatment with capecitabine increased disease-free and overall survival in breast cancer patients with residual disease after neoadjuvant chemotherapy, according to a study reported by researchers from Japan and Korea at the 2015 San Antonio Breast Cancer Symposium.1 “It has been unclear whether...
ESMO Asia 2015: Immunotherapy and Targeted Therapy Provide New Options for Difficult-to-Treat Head and Neck Cancer
Novel strategies are being explored for difficult-to-treat and advanced head and neck cancer—the most heterogeneous group of malignancies that are generally associated with poor survival—and encouraging results have been presented in two trials at the first European Society for Medical...
SABCS 2015: Capecitabine Improved Outcomes for Breast Cancer Patients With Residual Disease After Presurgery Chemotherapy
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer...
Study Finds Investigational Personalized Peptide Vaccination Increased Survival in Patients With Advanced Bladder Cancer
Although urothelial cancer of the bladder is sensitive to platinum-based chemotherapy, the vast majority of patients treated with these therapies will develop progressive disease within 8 months of treatment, and the median survival is reported to be between 13 and 15 months, according to a new...
ECC 2015: Lung and Gastrointestinal Neuroendocrine Tumors and Results From the RADIANT-4 Trial
An international team of researchers has shown that the use of the mTOR inhibitor everolimus can delay tumor growth among both gastrointestinal and lung neuroendocrine tumors. This is particularly important for patients with lung tumors, the researchers say, because there is currently no approved...
KW-0761 May Reduce Immune System–Suppressing Treg Cells in Patients With Solid Tumors
A small phase Ia clinical trial investigating whether depleting immune cells called Tregs, which can inhibit anticancer immune responses, with KW-0761, a humanized anti-CCR4 monoclonal antibody, in patients with lung or esophageal cancer has found that the therapy dramatically reduced the number of ...
Japanese Phase II Trial Shows Activity of Nivolumab in Platinum-Resistant Ovarian Cancer
In a Japanese phase II trial reported in the Journal of Clinical Oncology, Hamanishi et al found that the anti–PD-1 (programmed cell death protein 1) antibody nivolumab (Opdivo) was active in patients with relapsed or advanced platinum-resistant ovarian cancer. Study Details In the study,...
ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy
The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....
Analysis Shows New Cancer Cases Rise Globally, but Death Rates Decline in Many Countries
New cases of virtually all types of cancer are rising in countries globally—regardless of income—but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries. These findings were published by Fitzmaurice et al in JAMA...
TAS-102 Significantly Improves Overall Survival in Patients With Metastatic Colorectal Cancer
A large, phase III international study of the oral agent TAS-102 in patients with heavily pretreated metastatic colorectal cancer has found that the therapy improved overall survival by 1.8 months and also delayed disease progression. TAS-102 had few side effects and was also effective in patients...
One-Quarter of Advanced Lung Cancer Patients Tested for EGFR Mutations Started on First-Line Therapy Before Test Results Available
Almost one in four patients (24%) with advanced lung cancer in Europe, Asia, and the United States are not receiving EGFR test results before being started on treatment, researchers reported at the European Lung Cancer Conference (ELCC) in Geneva (Abstract LBA2_PR). This lack of test results may...
Japanese Study Indicates Death at Home Is Better for Terminally Ill Cancer Patients
In a Japanese study reported in the Journal of Clinical Oncology, Kinoshita et al found that death at home vs palliative care units or hospitals was better for terminally ill cancer patients and was not associated with an increased caregiver burden. Study Details The study included two...
Japanese Phase III Trial Shows No Survival Benefit of First-Line Weekly Cisplatin/Docetaxel vs Docetaxel in Elderly Patients With Advanced NSCLC
In a Japanese phase III trial (Intergroup Trial JCOG0803/WJOG4307L) reported in the Journal of Clinical Oncology, Abe et al found no overall survival benefit of weekly cisplatin/docetaxel vs standard docetaxel in the first-line treatment of elderly patients with advanced non–small cell lung...
Inherited Gene Variation Helps Explain Drug Toxicity in ALL Patients of East Asian Ancestry
Scientists at St. Jude Children's Research Hospital have discovered about 10% of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood ...
No Overall Survival Difference for Linifanib vs Sorafenib in Advanced Hepatocellular Carcinoma
In a phase III trial reported in the Journal of Clinical Oncology, Cainap et al found that treatment with linifanib, an ATP-competitive inhibitor of VEGF and PDGF receptor tyrosine kinases, did not improve overall survival compared with sorafenib (Nexavar) treatment in patients with advanced...
CONCORD-2 Study Reveals Wide Variability in Global Cancer Survival Rates
As reported in The Lancet by Allemani et al, the CONCORD-2 study of global cancer survival indicates improvements in survival in many countries in colorectal, breast, and prostate cancers, persistent poor outcomes in lung and liver cancers, and wide variability in survival in many cancers. The...
Neoadjuvant Chemotherapy Plus Two Anti-HER2 Agents Optimal for HER2-Positive Breast Cancer
For women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, combining two anti-HER2 agents with chemotherapy is the most effective treatment modality in the neoadjuvant setting, according to a meta-analysis published in the Journal of the National Cancer Institute. The...
New Findings in Acute Promyelocytic Leukemia
Three studies reported in the Journal of Clinical Oncology provide information on maintenance treatment with the synthetic retinoid tamibarotene in acute promyelocytic leukemia, potential implications of QT interval prolongation related to arsenic trioxide (Trisenox), and potential health-related...
FDG-PET Is Less Specific in Diagnosing Lung Cancer in Areas With Endemic Infectious Lung Disease
Although positron-emission tomography (PET) combined with 18F–fluorodeoxyglucose (FDG) is recommended for the noninvasive diagnosis of pulmonary nodules suspicious for lung cancer, in populations with endemic infectious lung disease, FDG-PET may not accurately identify malignant lesions. An...
Study Identifies Two Novel ALK Mutations Causing Lung Cancer Resistance to ALK Inhibitors
In a recent study investigating alectinib resistance in ALK-positive lung cancers, researchers identified two novel ALK mutations that are sensitive to ceritinib (Zykadia), a next-generation ALK tyrosine kinase inhibitor approved by the FDA earlier this year for advanced non–small cell lung...
Phase II Trial Shows Overall Survival Benefit With VT-122 Plus Sorafenib in Advanced Hepatocellular Carcinoma
The investigational agent VT-122 appeared to benefit survival when combined with sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma, according to data presented at the 8th Annual International Liver Cancer Association Conference in Kyoto, Japan. Researchers reported an 11-month...
Early Study Identifies Tumor-Suppressor Gene, Potential Therapy for Medulloblastoma
An international, multi-institutional research group led by scientists at the Cancer and Blood Diseases Institute (CBDI) at Cincinnati Children’s Hospital Medical Center has identified a novel molecular pathway that causes an aggressive form of medulloblastoma, The study, reported by He et al ...
Phase III Trial Shows Improved Survival With TAS-102 in Metastatic Colorectal Cancer Refractory to Standard Therapies
The new combination agent TAS-102 can improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract O-0022). “Around 50%...
Phase III Trial Indicates That S-1 Monotherapy Should Remain Standard Treatment of Locally Advanced Gastric Cancer in Japan
The oral fluoropyrimidine S-1 is standard treatment for locally advanced gastric cancer in Japan. In a Japanese phase III trial (SAMIT) in locally advanced disease reported in The Lancet Oncology, Tsuburaya et al found that sequential paclitaxel plus tegafur and uracil or S-1 did not improve...
Oncologist Communication Skills Training Program Effective for Both Oncologists and Patients
In a Japanese study reported in the Journal of Clinical Oncology, Fujimori et al found that an oncologist communication skills training program based on patient preferences in receiving bad news was of benefit to both oncologists and patients. Study Details In the study, 30 oncologists were...
Adding Lapatinib to Paclitaxel Does Not Improve Survival as Second-Line Therapy in Asian Patients With HER2-Positive Advanced Gastric Cancer
Weekly paclitaxel is used as second-line treatment in advanced gastric cancer, including HER2-positive disease, in Asian countries. In the phase III TyTAN trial in Asian patients reported in the Journal of Clinical Oncology, Satoh et al assessed the addition of the anti-HER2 agent lapatinib...
Increased Incidence of Thyroid Cancer: An Epidemic of Diagnosis?
In a study reported in JAMA Otolaryngology Head & Neck Surgery, Davies and Gilbert found that the incidence of thyroid cancer has nearly tripled since 1975. However, the increase appears to represent an “epidemic of diagnosis” and to almost exclusively represent increased diagnosis...
Disease-Free Survival Is Acceptable Surrogate for Overall Survival in Trials of Adjuvant Chemotherapy for Gastric Cancers
Disease-free survival is an acceptable surrogate for overall survival in trials of cytotoxic agents for gastric cancer in the adjuvant setting, the GASTRIC group concluded after conducting a meta-analysis of data from 3,288 individual patients enrolled in 14 randomized clinical trials. The trials...
Phase II Study Supports Axitinib Dose Titration in Select Treatment-Naive Metastatic Renal Cell Carcinoma Patients
Axitinib plasma exposure may correlate with efficacy in metastatic renal cell carcinoma, according to population pharmacokinetic data. In a phase II study reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic, and colleagues evaluated the effects of axitinib dose titration in...
Everolimus Does Not Improve Overall Survival in Previously Treated Advanced Gastric Cancer
In a phase III trial (GRANITE-1 study) reported in Journal of Clinical Oncology by Atsushi Ohtsu, MD, PhD, of the National Cancer Center Hospital East in Kashiwa, Japan, and colleagues, everolimus (Afinitor) plus best supportive care did not prolong overall survival compared with placebo plus best...
Japanese Study Shows Endoscopic Dual Tracer Method for Sentinel Node Mapping in Gastric Cancer Is Safe and Accurate
In a study reported in Journal of Clinical Oncology, Yuko Kitagawa, MD, FACS, of Keio University School of Medicine, and colleagues found that sentinel node mapping using a standardized dual tracer endoscopic injection technique was safe and accurate in patients with gastric cancer. Study Details ...
Carbon Ion Radiotherapy Safe and Effective for Treating Inoperable Spinal Tumors
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. The study, published online in Cancer, indicates that the treatment is a promising alternative for patients whose spinal tumors...
Critical Pathway in Cell Cycle May Lead to Cancer Development
A team of scientists at the Salk Institute for Biological Studies has identified why disruption of a vital pathway in cell cycle control leads to the proliferation of cancer cells. Their findings on telomeres, published today in Molecular Cell, suggest a potential target for preventive measures...
Chernobyl Follow-up Study Finds High Survival Rate among Young Thyroid Cancer Patients
More than a quarter of a century after the Chernobyl nuclear disaster, many children and teenagers who developed thyroid cancer due to radiation are in complete or near remission, according to a recent study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology ...
New Metabolite-based Diagnostic Test Could Help Detect Pancreatic Cancer Early
A new diagnostic test that uses a technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection. Researchers examined the utility of metabolomic analysis as a diagnostic method for...
